On 16 and 17 of June, members of our consortium from across Europe came together for a dedicated two-day general meeting focused on shaping the future of antiviral development. This exclusive meeting was designed to foster strategic dialogue, operational alignment, and scientific exchange among project partners, creating space for deeper collaboration and forward-looking vision.
Throughout the event, we monitored and evaluate the current status of the project, examining achievements to date, unresolved challenges, and next steps.
This meeting provided also the opportunity to connect more closely with fellow consortium members, strengthen the coherence of our multi-disciplinary efforts, and identify new synergies that can shape the second phase of the project. Communication, dissemination, and the broader societal impact of AVITHRAPID was at the heart of the discussions, ensuring that our scientific progress is aligned with the real-world needs we aim to address.
